ULTRAGENYX PHARMACEUTICAL IN's ticker is RARE and the CUSIP is 90400D108. A total of 165 filers reported holding ULTRAGENYX PHARMACEUTICAL IN in Q4 2018. The put-call ratio across all filers is 1.21 and the average weighting 0.1%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $13,359,373 | -19.3% | 374,737 | +4.4% | 0.00% | -50.0% |
Q2 2023 | $16,554,488 | -12.3% | 358,866 | -23.8% | 0.00% | 0.0% |
Q1 2023 | $18,885,094 | +3.9% | 470,950 | +20.0% | 0.00% | 0.0% |
Q4 2022 | $18,179,614 | +2.8% | 392,394 | -8.1% | 0.00% | 0.0% |
Q3 2022 | $17,689,000 | -28.3% | 427,196 | +3.3% | 0.00% | -33.3% |
Q2 2022 | $24,683,000 | +1.3% | 413,731 | +23.3% | 0.00% | +50.0% |
Q1 2022 | $24,364,000 | +17.4% | 335,483 | +35.9% | 0.00% | 0.0% |
Q4 2021 | $20,754,000 | -13.1% | 246,796 | -6.8% | 0.00% | 0.0% |
Q3 2021 | $23,889,000 | +5.9% | 264,873 | +12.0% | 0.00% | 0.0% |
Q2 2021 | $22,550,000 | -39.9% | 236,508 | -28.2% | 0.00% | -50.0% |
Q1 2021 | $37,493,000 | -6.1% | 329,301 | +14.2% | 0.00% | -20.0% |
Q4 2020 | $39,911,000 | +80.2% | 288,313 | +7.0% | 0.01% | +66.7% |
Q3 2020 | $22,151,000 | +40.2% | 269,518 | +33.5% | 0.00% | +50.0% |
Q2 2020 | $15,794,000 | +28.5% | 201,905 | -27.0% | 0.00% | 0.0% |
Q1 2020 | $12,294,000 | +47.1% | 276,712 | +41.4% | 0.00% | +100.0% |
Q4 2019 | $8,358,000 | +40.8% | 195,681 | +41.0% | 0.00% | 0.0% |
Q3 2019 | $5,938,000 | -41.7% | 138,822 | -13.4% | 0.00% | -50.0% |
Q2 2019 | $10,183,000 | +13.4% | 160,367 | +23.9% | 0.00% | +100.0% |
Q1 2019 | $8,980,000 | +238.7% | 129,464 | +112.4% | 0.00% | – |
Q4 2018 | $2,651,000 | -31.3% | 60,944 | +20.5% | 0.00% | -100.0% |
Q3 2018 | $3,861,000 | -23.7% | 50,579 | -23.1% | 0.00% | 0.0% |
Q2 2018 | $5,058,000 | +144.3% | 65,791 | +62.2% | 0.00% | – |
Q1 2018 | $2,070,000 | +32.9% | 40,572 | +20.7% | 0.00% | – |
Q4 2017 | $1,558,000 | -58.1% | 33,605 | -51.8% | 0.00% | -100.0% |
Q3 2017 | $3,716,000 | +35.9% | 69,773 | +58.5% | 0.00% | 0.0% |
Q2 2017 | $2,734,000 | -17.5% | 44,024 | -9.9% | 0.00% | 0.0% |
Q1 2017 | $3,313,000 | +6.0% | 48,877 | +9.9% | 0.00% | 0.0% |
Q4 2016 | $3,126,000 | +10.0% | 44,460 | +10.9% | 0.00% | 0.0% |
Q3 2016 | $2,843,000 | +57.2% | 40,083 | +8.5% | 0.00% | – |
Q2 2016 | $1,808,000 | -1.8% | 36,955 | +27.2% | 0.00% | – |
Q1 2016 | $1,841,000 | -64.0% | 29,061 | -36.2% | 0.00% | -100.0% |
Q4 2015 | $5,111,000 | +14.5% | 45,560 | -1.7% | 0.00% | 0.0% |
Q3 2015 | $4,463,000 | +375.3% | 46,336 | +405.5% | 0.00% | – |
Q2 2015 | $939,000 | +1856.2% | 9,166 | +1073.6% | 0.00% | – |
Q1 2015 | $48,000 | -61.3% | 781 | -72.4% | 0.00% | – |
Q4 2014 | $124,000 | +226.3% | 2,827 | +317.6% | 0.00% | – |
Q3 2014 | $38,000 | -90.4% | 677 | -92.3% | 0.00% | – |
Q2 2014 | $396,000 | +1265.5% | 8,816 | +1369.3% | 0.00% | – |
Q1 2014 | $29,000 | – | 600 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
GREAT POINT PARTNERS LLC | 727,426 | $25,932,737 | 4.72% |
RTW INVESTMENTS, LP | 5,405,089 | $192,691,423 | 4.07% |
First Light Asset Management, LLC | 1,125,032 | $40,107,391 | 3.81% |
CHI Advisors LLC | 215,000 | $7,664,750 | 3.04% |
INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 250,052 | $8,914,354 | 3.00% |
SPHERA FUNDS MANAGEMENT LTD. | 259,135 | $9,238,163 | 1.68% |
Rock Springs Capital Management LP | 1,476,441 | $52,635,122 | 1.41% |
SUVRETTA CAPITAL MANAGEMENT, LLC | 679,459 | $24,222,713 | 1.31% |
Privium Fund Management B.V. | 115,241 | $4,108,341 | 1.22% |
SECTOR GAMMA AS | 115,166 | $4,105,668 | 1.05% |